Showing 1521-1530 of 1644 results for "".
- New Study Examines the Risk of Relapse in Those Discontinuing MS Therapyhttps://practicalneurology.com/news/new-study-examines-the-risk-of-relapse-in-those-discontinuing-ms-therapy/2470432/The discontinuation of high-efficacy therapies (HETs) that impact immune cell trafficking, including Tysabri (natalizumab; Biogen, Cambridge, MA) and Gilenya (fingolimod; Novartis, East Hanover, NJ), in people aged ≥50 years with nonactive multiple sclerosis (MS) was associated with a signific
- No Benefit Seen with Adding Blood Thinners to r-TPA for Ischemic Stroke Treatmenthttps://practicalneurology.com/news/adding-blood-thinners-to-r-tpa-for-ischemic-stroke-treatment-does-not-improve-outcomes/2470398/The addition of blood thinners to standard thrombolytic therapy for ischemic stroke did not significantly improve patient physical function compared with the use of thrombolysis alone, according to results of a large clinical trial presented at the American Stroke Association’s Internationa
- New Guidelines for Comprehensive Epilepsy Care Publishedhttps://practicalneurology.com/news/new-guidelines-for-specialized-epilepsy-care-centers-published/2470396/The National Association of Epilepsy Centers (NAEC) has published the first updated guidelines for specialized epilepsy centers in over a decade. The recommendations provide a comprehensive framework for delivering high-quality care for the estimated 3.4 million people in the United States living
- Blood-Based Biomarker Test Highly Effective At Identifying Those at Risk of Developing Parkinson Diseasehttps://practicalneurology.com/news/blood-based-biomarker-test-highly-effective-at-identifying-those-at-risk-of-developing-parkinson-disease/2470393/Study results published in JAMA Neurology demonstrated an association between elevated L1CAM-positive extracellular vesicle (L1EV) α-synuclein serum levels and the risk of developing Parkinson disease (PD) or related dementia. The retrospective, cross-sectional multicente
- Commercially Available Plasma p-tau217 Biomarker Immunoassay for Alzheimer Disease as Accurate as CSF Biomarker Testing According to New Studyhttps://practicalneurology.com/news/commercially-available-plasma-p-tau217-biomarker-test-for-alzheimer-disease-as-accurate-as-csf-biomarker-testing-according-to-new-study/2470388/Results of a study published in JAMA Neurology demonstrated the high diagnostic accuracy and consistency of a commercially available phosphorylated tau at threonine 217 (p-tau217) test (ALZpath, Carlsbad, CA) in identifying abnormal amyloid beta (Aβ) and tau concentrations associate
- MS Susceptibility Genes Introduced to Europe 5000 Years Ago According to Study Published in Naturehttps://practicalneurology.com/news/ms-susceptibility-genes-introduced-to-europe-5000-years-ago-according-to-study-published-in-nature/2470382/Genes associated with susceptibility for multiple sclerosis (MS) may have been introduced to Northern Europe 5000 years ago, according to new study results published in Nature. The study was conducted to investigate potential causes for the significantly greater prevalence of MS among Wh
- Combination Therapy More Effective than Aspirin Alone For Stroke Prevention According to INSPIRES Clinical Trialhttps://practicalneurology.com/news/combination-therapy-more-effective-than-aspirin-alone-for-stroke-prevention-according-to-inspires-clinical-trial/2470373/Combination therapy, consisting of clopidogrel with aspirin, initiated within 72 hours of stroke onset in people with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause, was associated with a lower risk of new stroke at 90 days compared to the use
- FDA Grants Orphan Drug Designation to AAV Gene Therapy Product for Malignant Gliomahttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-to-aav-gene-therapy-product-for-malignant-glioma/2470368/NXL-004 (NeuExcell Therapeutics, Philadelphia, PA) has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA). NXL-004 is the first investigational adeno-associated virus vector (AAV) gene therapy product developed as a potential treatment for malignant glioma to rec
- AMA Issues New Principles for AI Development, Deployment, and Usehttps://practicalneurology.com/news/ama-issues-new-principles-for-ai-development-deployment-and-use-2/2470352/The American Medical Association (AMA) announced the release of new principles for augmented intelligence (AI) development, deployment, and use. According to the AMA, these principles represent a critical step toward fostering a consistent governance structure for advancements in health care tech
- Gantenerumab Did Not Slow Cognitive Decline in People with Early Alzheimer Disease According to 2 Clinical Trial Resultshttps://practicalneurology.com/news/ganenterumab-did-not-slow-cognitive-decline-in-people-with-early-alzheimer-disease-according-to-2-clinical-trial-results/2470338/Treatment with the monoclonal antibody (mAb) gantenerumab (Genentech, South San Francisco, CA; Roche, Basel, Switzerland) was associated with a lower amyloid plaque burden in people with early Alzheimer disease (AD), but it did not slow cognitive decline after 116 weeks. These findings are from t